This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16. No human anti-fusion protein antibodies (HAFA) response was detected. This immunocytokine was designed for treating metastatic breast cancer.

Specifications

Target
TnC-A1

Molecule Class
scFv-IL2

Species Reactivity
Human

Expression Host
CHO

Clone
F16

Related Disease
Metastatic breast cancer

Cytokine 1
IL2

Cytokines 1 Description
Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes.